Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-09

Study Completion Date

2024-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, single-center, fixed-sequence, nonrandomized, open-label study in healthy adults to investigate the impact of rifabutin on the pharmacokinetics of trikafta.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects

NCT01888393

Hepatic Impairment Healthy

COMPLETED PHASE1

Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib

NCT00864487

Healthy Subjects

COMPLETED PHASE1

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

NCT00819468

Hepatic Impairment

COMPLETED PHASE1

Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

NCT02244827

Hepatic Impairment

COMPLETED PHASE1

Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

NCT03423446

Hepatic Impairment

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Trikafta (Elexacaftor \[ELX\], Tezacaftor \[TEZ\], Ivacaftor\[IVA\]) is contraindicated with concomitant use of strong inducers as co-administration of rifampin decreased the area-under-the concentration time curve (AUC) of IVA by 89%, creating a therapeutic challenge to the treatment of non-tuberculosis mycobacteria (NTM) infection in people with cystic fibrosis (CF). While rifabutin also induces CYP3A4 activity, its effects appear to be more moderate when compared with rifampin. Therefore, we hypothesize that rifabutin can be co-administered with an adjusted dose of ELX/TEZ/IVA in patients being treated for NTM pulmonary disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Drug Interaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

A single group of subjects will receive a single dose of trikafta (orange tablet) in period 1. After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on day 1 through 17 and a single dose of trikafta (orange tablet) on day 15 in period 2.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

rifabutin

Rifabutin PO \[two 150mg capsules\] ; Trikafta PO \[one orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg\]

Group Type EXPERIMENTAL

Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]

Intervention Type DRUG

Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.

Rifabutin 300mg

Intervention Type DRUG

After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]

Subjects will receive a single dose of trikafta (orange tablet) on day 1 of period 1 and on day 15 of period 2.

Intervention Type DRUG

Rifabutin 300mg

After washout period greater or equal to 2 days, subjects will receive 300 mg/d of rifabutin on days 1 through 17 of period 2.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able and willing to sign informed consent prior to any study-related activities.
* Male or female participants between 18 and 65 years of age inclusive.
* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination findings, and clinical laboratory test results
* Body mass index (BMI) of 17.5 to 30.5 kg/m2, inclusive; and a total body weight \>50kg (110 lbs).
* Willing to stop using any herbal or natural health products for 2 weeks prior to and during the study including: Grapefruit, grapefruit juice, St. John's Wort.
* Participant must use a reliable method of birth control while they are participating in the study; for instance an intrauterine device (IUD), condom with spermicidal gel or foam, diaphragm with spermicidal gel or foam, vasectomy, tubal ligation, hysterectomy or abstinence or female must be post-menopausal for at least one year.

Exclusion Criteria

* Female subjects of childbearing potential with positive urine pregnancy test at screening.
* Female subjects who are breastfeeding.
* Use of CYP3A modulators (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin, azole drugs, telithromycin, clarithromycin, erythromycin)
* Any significant acute or chronic medical illness that might confound the results of the study or pose an additional risk in administrating study drugs to the subject, as determined by the investigator.
* Any condition that could affect drug absorption (eg, gastrectomy, pancreatitis).
* Any major surgery within 4 weeks of study drug administration.
* Blood donation of approximately 1 pint (500 mL) within 56 days before study drug administration.
* Known hypersensitivity to rifamycins
* Patients with hepatic impairment (Child-Pugh Class B or C) and/or with history of hepatobiliary disease or liver function test elevations.
* Renal insufficiency (eGFR \< 60 mL/min)
* History of uveitis and/or current eye or vision problems with the exception of corrective lenses.
* Contact lens use during study drug administration.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes